Pre-Test When to Treat Waldenstrom’s Macroglobulinemia and How to Sequence Therapy Pre-Test 1. Which of the following BTK inhibitors demonstrated an overall response rate of 100% as a monotherapy in patients with Waldenstrom’s macroglobulinemia (WM) in a phase 2 clinical trial? Acalabrutinib Ibrutinib Pirtobrutinib Zanubrutinib Unsure 2. Which of the following mutation combinations in WM is associated with improved patient response to ibrutinib monotherapy? MYD88 mutant, CXCR4 mutant MYD88 mutant, CXCR4 wildtype MYD88 wildtype, CXCR4 mutant MYD88 wildtype, CXCR4 wildtype E. Unsure 3. The phase 3 ASPEN trial compared _____________ to ibrutinib in patients with WM and demonstrated a lower discontinuation rate due to treatment-related adverse events. Acalabrutinib Pirtobrutinib Venetoclax Zanubrutinib Unsure 4. How confident are you in your ability to select and sequence therapies for WM using the latest evidence? Very Confident Confident Somewhat confident Not very confident Not at all confident
